Abstract
Objectives: Evidence suggests that B cell-depleting therapy with rituximab (RTX) affects humoral immune response after vaccination. It remains unclear whether RTX-treated patients can develop a humoral and T-cell-mediated immune response against SARS-CoV-2 after immunisation.
Methods: Patients under RTX treatment (n=74) were vaccinated twice with either mRNA-1273 or BNT162b2. Antibodies were quantified using the Elecsys Anti-SARS-CoV-2 S immunoassay against the receptor-binding domain (RBD) of the spike protein and neutralisation tests. SARS-CoV-2-specific T-cell responses were quantified by IFN-γ enzyme-linked immunosorbent spot assays. Prepandemic healthy individuals (n=5), as well as healthy individuals (n=10) vaccinated with BNT162b2, served as controls.
Results: All healthy controls developed antibodies against the SARS-CoV-2 RBD of the spike protein, but only 39% of the patients under RTX treatment seroconverted. Antibodies against SARS-CoV-2 RBD significantly correlated with neutralising antibodies (τ=0.74, p<0.001). Patients without detectable CD19 + peripheral B cells (n=36) did not develop specific antibodies, except for one patient. Circulating B cells correlated with the levels of antibodies (τ=0.4, p<0.001). However, even patients with a low number of B cells (<1%) mounted detectable SARS-CoV-2-specific antibody responses. SARS-CoV-2-specific T cells were detected in 58% of the patients, independent of a humoral immune response.
Conclusions: The data suggest that vaccination can induce SARS-CoV-2-specific antibodies in RTX-treated patients, once peripheral B cells at least partially repopulate. Moreover, SARS-CoV-2-specific T cells that evolved in more than half of the vaccinated patients may exert protective effects independent of humoral immune responses.
Keywords: COVID-19; rituximab; vaccination.
【저자키워드】 COVID-19, rituximab, vaccination., 【초록키워드】 Treatment, SARS-CoV-2, immune response, vaccination, therapy, antibody, T cells, mRNA-1273, Neutralising Antibodies, B cells, rituximab, Spike protein, B cell, BNT162b2, immunoassay, Protective effects, Receptor-binding domain, RBD, mRNA, neutralising antibody, immune responses, Patient, immunisation, humoral immune response, humoral immune responses, SARS-CoV-2-specific antibodies, patients, neutralisation, T-cell responses, SARS-CoV-2-specific T cells, protective effect, IFN-γ, specific antibodies, humoral, CD19, SARS-CoV-2 RBD, except for, independent of, SARS-CoV-2-specific antibody, enzyme, healthy control, healthy individuals, one patient, n=36, SARS-CoV-2-specific T-cell responses, Affect, responses, controls, independent, enzyme-linked immunosorbent, neutralisation tests, peripheral B cells, develop, significantly, the patient, assays, detectable, seroconverted, the spike protein, correlated, the receptor-binding domain, induce, healthy individual, quantified, Elecsy, levels of antibody, mounted, peripheral B cell, RTX, SARS-CoV-2-specific T cell, SARS-CoV-2-specific T-cell response, the SARS-CoV-2, 【제목키워드】 B cell, SARS-CoV-2 vaccination, T-cell-mediated immunity, promote,